CANCER IMMUNOTHERAPY MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global cancer immunotherapy market is estimated to be valued at USD 158.42 Bn in 2025 and is expected to exhibit a CAGR of 12.3% during the forecast period (2025-2032). Cancer immunotherapy is a type of cancer treatment that utilizes the body's own immune system to fight against cancer. It is an innovative approach that harnesses the power of the immune system and modifies it to enhance the body's natural defenses against cancer. Cancer immunotherapy comprises therapies like monoclonal antibodies, checkpoint inhibitors, interleukin inhibitors, therapeutic cancer vaccines and others. It is gaining prominence as recent scientific breakthroughs have improved understanding of the complex interaction between tumor cells and the immune system. Cancer immunotherapy represents a novel treatment paradigm that has the potential to transform the way cancer is treated in the future.

Market Dynamics

Global cancer immunotherapy market growth is driven by factors such as increasing prevalence of cancer worldwide, rising demand for effective targeted therapies, and higher treatment success rates associated with cancer immunotherapy as compared to conventional treatment modalities. Cancer remains one of the leading causes of mortality and the global burden of cancer is expected to rise significantly in the near future. This is providing a major boost to immunotherapy adoption. Advancements in biotechnology along with better understanding of cancer immunology have led to the development of novel immunotherapies, which are paving the way for improved patient outcomes. However, high costs associated with immunotherapy drugs, need for specialized infrastructure and healthcare personnel, and safety concerns related to immunotherapy are some of the challenges restraining the market growth. Active R&D in this field, targeting new cancer types, and ongoing clinical trials hold potential to provide growth opportunities for market players.

Key Features of the Study

• This report provides in-depth analysis of the global cancer immunotherapy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global cancer immunotherapy market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Gilead Sciences, Inc., Johnson & Johnson, Actym Therapeutics, Inc., Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Merck & Co., Inc., Fate Therapeutics., AstraZeneca, Amgen Inc., GSK plc., Acumen Pharmaceuticals, Inc, Arcus Biosciences, Inc., BioNTech SE, Cellectis, immunitybio inc, Autolus Therapeutics, ADC Therapeutics SA., Gritstone bio, and Incyte.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global cancer immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer immunotherapy market.

Market Segmentation

• Therapy Type Insights (Revenue, USD Bn, 2020 - 2032)
• Immune checkpoint inhibitors
• Vaccines
• Preventive Vaccines
• Therapeutic Vaccines
• Adoptive Cell Therapies
• Tumor-infiltrating lymphocyte (TIL) therapy
• CAR T-cell therapy
• Engineered T-cell receptor (TCR) therapy
• Natural killer (NK) cell therapy
• Immune System Modulators
• Interferons
• Immunomodulators (IMiDs)
• Interleukins
• Monoclonal antibodies
• Naked monoclonal antibodies
• Conjugated monoclonal antibodies
• Bispecific monoclonal antibodies
• Oncolytic Virus Therapy
• Route Of Administration Insights (Revenue, USD Bn, 2020 - 2032)
• Subcutaneous 
• Oral
• Intramuscular
• Intravenous (IV)
• Other
• Cancer Type Insights (Revenue, USD Bn, 2020 - 2032)
• Lymphoma
• Breast Cancer
• Colorectal Cancer
• Bladder Cancer
• Skin Cancer
• Lung Cancer
• Kidney Cancer
• Others
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Gilead Sciences, Inc.
• Johnson & Johnson
• Actym Therapeutics, Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc
• Novartis AG
• Merck & Co., Inc.
• Fate Therapeutics .
• AstraZeneca
• Amgen Inc.
• GSK plc.
• Acumen Pharmaceuticals, Inc.
• Arcus Biosciences, Inc.
• BioNTech SE
• Cellectis
• immunitybio Inc.
• Autolus Therapeutics
• ADC Therapeutics SA.
• Gritstone bio
• Incyte